emibetuzumab   Click here for help

GtoPdb Ligand ID: 7748

Synonyms: LA480 | LY-2875358 | LY2875358
Compound class: Antibody
Comment: Emibetuzumab is an investigatonal monoclonal antibody designed as a potential treatment for advanced or metastatic solid tumors.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Davies J, Liu L, Lu J, Vaillancourt PE, Wortinger MA, Zeng W. 
c-Met antibodies.
Patent number: US8217148. Assignee: Eli Lilly And Company. Priority date: 21/11/2008. Publication date: 10/07/2012.
2. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J et al.. (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Science, 316 (5827): 1039-43. [PMID:17463250]
3. Liu L, Zeng W, Wortinger MA, Yan SB, Cornwell P, Peek VL, Stephens JR, Tetreault JW, Xia J, Manro JR et al.. (2014)
LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.
Clin Cancer Res, 20 (23): 6059-70. [PMID:25231402]
4. McDermott U, Pusapati RV, Christensen JG, Gray NS, Settleman J. (2010)
Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency.
Cancer Res, 70 (4): 1625-34. [PMID:20124471]
5. Yano S, Takeuchi S, Nakagawa T, Yamada T. (2012)
Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands.
Cancer Sci, 103 (7): 1189-94. [PMID:22435662]